Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cáncer de Recto 3 study

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 859-865

  Fernández Martos, Carlos ^a   Pericay, Carles ^a   Aparicio, Jorge ^a   Salud, Antonieta ^a   Safont, MariaJose ^a   Massuti, Bertomeu ^a   Vera, Ruth ^a   Escudero, Pilar ^a   Maurel, Joan ^a   Marcuello, Eugenio ^a   Mengual, Jose Luis ^a   Saigi, Eugenio ^a   Estevan, Rafael ^a   Mira, Moises ^a   Polo, Sonia ^a   Hernandez, Ana ^a   Gallen, Manuel ^a   Arias, Fernando ^a   Serra, Javier ^a   Alonso, Vicente ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; TUMOR REGRESSION; ABDOMINAL SURGERY; ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; DIET THERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RECTUM TUMOR; RISK ASSESSMENT; SPAIN; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK ASSESSMENT; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649209505     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.8541     Document Type: Article

References (18)

1. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
2. Bosset JF, Collette L, Calais G, et al: Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. N Engl J Med; 355:1114-1123, 2006 (Pubitemid 44394918)
3. Gérard JP, Conroy T, Bonnetain F, et al: Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. J Clin Oncol 24:4620-4625, 2006 (Pubitemid 46630960)
4. Rödel C, Liersch T, Hermann R, et al: Multicenter Phase II Trial ofChemoradiation With Oxaliplatin for Rectal Cancer. J Clin Oncol 25:668-674, 2007
5. Sebag-Montefiore D, Rutten H, Rullier E, et al: Three-year survival results of CORE (Capecitabine, Oxaliplatin, Radiotherapy, and Excision) study after postoperative chemotherapy in patients with locally advanced rectal adenocarcinoma. ASCO GI Meeting Abstracts. 447, Jan 2009
6. Glynne-Jones R, Grainger J, Harrison J, et al: Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: Should we be more cautious? Br J Cancer 94:363-371, 2006
7. Chau I, Brown G, Cunningham D, et al: Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer. J Clin Oncol 24:668-674, 2006 (Pubitemid 46630432)
8. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 http://ctep.cancer.gov
9. Quirke P, Williams GT: Minimum Dataset for Colorectal Cancer Histopathology Reports. London: Royal College of Pathologists. 1998
10. Greene FL, Page DL, Fleming ID, et al: Colon and Rectum, AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, pp 113-124, 2002
11. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-23, 1997 (Pubitemid 27138353)
12. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989 (Pubitemid 19099520)
13. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381, 1985
14. Machiels JP, Duck L, Honhon B, et al: Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: The RadiOxCape study. Ann Oncol 16:1898-1905, 2005
15. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al: A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 17:50-56, 2006
16. Aschele C, Pinto C, Cordio S, et al: Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 27:18s, 2009 (suppl; abstr CRA 4008)
17. Gerard J, Azria D, Gourgou-Bourgade S, et al: Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2. J Clin Oncol 27:18s, 2009 (suppl; abstr LBA4007)
18. Minsky B: Adjuvant management of rectal cancer: The more we learn, the less we know. J Clin Oncol 25:4339-4340, 2007 (Pubitemid 350013835)